User menu

Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Bibliographic reference Van Bambeke, Françoise. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.. In: Drugs, Vol. 75, no.18, p. 2073-2095 (2015)
Permanent URL
  1. COOPER ROBIN D. G., SNYDER NANCY J., ZWEIFEL MARK J., STASZAK MICHAEL A., WILKIE STEPHEN C., NICAS THALIA I., MULLEN DEBORAH L., BUTLER THOMAS F., RODRIGUEZ MICHAEL J., HUFF BRET E., THOMPSON RICHARD C., Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity., 10.7164/antibiotics.49.575
  2. Allen NE. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. AntiInf Ag Med Chem. 2010;9:23–47.
  3. Dunbar L. M., Milata J., McClure T., Wasilewski M. M., , Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial, 10.1128/aac.00029-11
  4. Darpo Borje, Lee Sun K., Moon Thomas E., Sills Nancy, Mason Jay W., Oritavancin, a New Lipoglycopeptide Antibiotic: Results From a Thorough QT Study, 10.1177/0091270009355449
  5. Bambeke Françoise Van, Glycopeptides in clinical development: pharmacological profile and clinical perspectives, 10.1016/j.coph.2004.04.006
  6. The Medicines Company. Orbactiv™ full prescribing information. . Accessed 29 Aug 2015.
  7. The Medicines Company. Orbactiv™ summary of product characteristics. . Accessed 29 Aug 2015.
  9. Wenzler Eric, Rodvold Keith A., Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions, 10.1093/cid/civ522
  10. Theravance BioPharma. Vibativ™ full prescribing information. . Accessed 29 Aug 2015.
  11. Clinigen Healthcare Ltd. Vibativ™ summary of product characteristics. . Accessed 29 Aug 2015.
  12. MALABARBA ADRIANO, CIABATTI ROMEO, KETTENRING JÜRGEN, FERRARI PIETRO, SCOTTI ROBERTO, GOLDSTEIN BETH P., DENARO MAURIZIO, Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity., 10.7164/antibiotics.47.1493
  13. MALABARBA ADRIANO, CIABATTI ROMEO, SCOTTI ROBERTO, GOLDSTEIN BETH P., FERRARI PIETRO, KURZ MICHAEL, ANDREINI BIANCA P., DENARO MAURIZIO, New Semisynthetic Glycopeptides MDL 63,246 and MDL 63,042, and Other Amide Derivatives of Antibiotic A-40,926 Active against Highly Glycopeptide-resistant VanA Enterococci., 10.7164/antibiotics.48.869
  14. Durata Therapeutics. Dalvance™ full prescribing information. . Accessed 29 Aug 2015.
  15. Durata Therapeutics, Durata. Xydalba™ summary of product characteristics. . Accessed 29 Aug 2015.
  16. Butler Mark S, Hansford Karl A, Blaskovich Mark A T, Halai Reena, Cooper Matthew A, Glycopeptide antibiotics: Back to the future, 10.1038/ja.2014.111
  17. Barna J C J, Williams D H, The Structure and Mode of Action of Glycopeptide Antibiotics of the Vancomycin Group, 10.1146/annurev.mi.38.100184.002011
  18. Reynolds P. E., Structure, biochemistry and mechanism of action of glycopeptide antibiotics, 10.1007/bf01967563
  19. Lamp K C, Rybak M J, Bailey E M, Kaatz G W, In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin., 10.1128/aac.36.12.2709
  20. Hiramatsu K, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, 10.1093/jac/40.1.135
  21. Gardete Susana, Tomasz Alexander, Mechanisms of vancomycin resistance in Staphylococcus aureus, 10.1172/jci68834
  22. Courvalin Patrice, Vancomycin Resistance in Gram-Positive Cocci, 10.1086/491711
  23. Gould I.M., Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA), 10.1016/j.ijantimicag.2013.04.006
  24. Beauregard D. A., Williams D. H., Gwynn M. N., Knowles D. J., Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics, 10.1128/aac.39.3.781
  25. Van Bambeke Fran??oise, Van Laethem Yves, Courvalin Patrice, Tulkens Paul M, Glycopeptide Antibiotics : from Conventional Molecules to New Derivatives, 10.2165/00003495-200464090-00001
  26. Allen Norris E., Nicas Thalia I., Mechanism of action of oritavancin and related glycopeptide antibiotics, 10.1111/j.1574-6976.2003.tb00628.x
  27. Cheng Mu, Ziora Zyta M., Hansford Karl A., Blaskovich Mark A., Butler Mark S., Cooper Matthew A., Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin, 10.1039/c3ob42428f
  28. Economou Nicoleta J., Nahoum Virginie, Weeks Stephen D., Grasty Kimberly C., Zentner Isaac J., Townsend Tracy M., Bhuiya Mohammad W., Cocklin Simon, Loll Patrick J., A Carrier Protein Strategy Yields the Structure of Dalbavancin, 10.1021/ja208755j
  29. Belley A., McKay G. A., Arhin F. F., Sarmiento I., Beaulieu S., Fadhil I., Parr T. R., Moeck G., Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing, 10.1128/aac.00760-10
  30. Higgins D. L., Chang R., Debabov D. V., Leung J., Wu T., Krause K. M., Sandvik E., Hubbard J. M., Kaniga K., Schmidt D. E., Gao Q., Cass R. T., Karr D. E., Benton B. M., Humphrey P. P., Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus, 10.1128/aac.49.3.1127-1134.2005
  31. Belley A., Harris R., Beveridge T., Parr T., Moeck G., Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus, 10.1128/aac.00603-08
  32. Messina Julia A, Fowler Vance G, Corey G Ralph, Oritavancin for acute bacterial skin and skin structure infections, 10.1517/14656566.2015.1026256
  33. Lunde C. S., Hartouni S. R., Janc J. W., Mammen M., Humphrey P. P., Benton B. M., Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II, 10.1128/aac.01710-08
  34. Song Y., Lunde C. S., Benton B. M., Wilkinson B. J., Further Insights into the Mode of Action of the Lipoglycopeptide Telavancin through Global Gene Expression Studies, 10.1128/aac.05403-11
  35. Barcia-Macay M., Lemaire S., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, 10.1093/jac/dkl424
  36. Domenech Oscar, Dufrêne Yves F., Van Bambeke Françoise, Tukens Paul M., Mingeot-Leclercq Marie-Paule, Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus, 10.1016/j.bbamem.2010.06.011
  37. Münch Daniela, Engels Ina, Müller Anna, Reder-Christ Katrin, Falkenstein-Paul Hildegard, Bierbaum Gabriele, Grein Fabian, Bendas Gerd, Sahl Hans-Georg, Schneider Tanja, Structural Variations of the Cell Wall Precursor Lipid II and Their Influence on Binding and Activity of the Lipoglycopeptide Antibiotic Oritavancin, 10.1128/aac.02663-14
  38. Kim Sung Joon, Cegelski Lynette, Stueber Dirk, Singh Manmilan, Dietrich Evelyne, Tanaka Kelly S.E., Parr Thomas R., Far Adel Rafai, Schaefer Jacob, Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus, 10.1016/j.jmb.2008.01.031
  39. Patti Gary J., Kim Sung Joon, Yu Tsyr-Yan, Dietrich Evelyne, Tanaka Kelly S.E., Parr Thomas R., Far Adel Rafai, Schaefer Jacob, Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium, 10.1016/j.jmb.2009.06.064
  40. Mendes Rodrigo E., Farrell David J., Sader Helio S., Flamm Robert K., Jones Ronald N., Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method, 10.1128/aac.04052-14
  41. Arhin F. F., Sarmiento I., Belley A., McKay G. A., Draghi D. C., Grover P., Sahm D. F., Parr T. R., Moeck G., Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing, 10.1128/aac.01513-07
  42. Rennie R. P., Koeth L., Jones R. N., Fritsche T. R., Knapp C. C., Killian S. B., Goldstein B. P., Factors Influencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent, 10.1128/jcm.02411-06
  43. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: 25th informational supplement (MS100-S25). Wayne: Clinical and Laboratory Standard Institute; 2015.
  44. Arhin Francis F., Draghi Deborah C., Pillar Chris M., Moeck Gregory, Sahm Daniel F., Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci, 10.1016/j.ijantimicag.2012.06.019
  45. Jones Ronald N., Turnidge John D., Moeck Greg, Arhin Francis F., Mendes Rodrigo E., Use ofIn VitroVancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide, 10.1128/aac.05098-14
  46. Jones Ronald N., Farrell David J., Flamm Robert K., Sader Helio S., Dunne Michael W., Mendes Rodrigo E., Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin, 10.1016/j.diagmicrobio.2015.01.017
  47. Saravolatz Louis D., Pawlak Joan, Johnson Leonard B., In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA), 10.1016/j.ijantimicag.2010.02.023
  48. Hill C. M., Krause K. M., Lewis S. R., Blais J., Benton B. M., Mammen M., Humphrey P. P., Kinana A., Janc J. W., Specificity of Induction of the vanA and vanB Operons in Vancomycin-Resistant Enterococci by Telavancin, 10.1128/aac.01737-09
  49. Streit Jennifer M., Sader Helio S., Fritsche Thomas R., Jones Ronald N., Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens, 10.1016/j.diagmicrobio.2005.03.004
  50. Karlowsky J.A., Walkty A.J., Baxter M.R., Adam H.J., Zhanel G.G., In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013, 10.1016/j.diagmicrobio.2014.09.003
  51. Citron Diane M., Tyrrell Kerin L., Goldstein Ellie J.C., Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains, 10.1016/j.diagmicrobio.2014.05.014
  52. Biavasco F, Vignaroli C, Lupidi R, et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. 1997;41(10):2165–72.
  53. O'Connor R., Baines S. D., Freeman J., Wilcox M. H., In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin, 10.1093/jac/dkn276
  54. Goldstein Ellie J.C., Citron Diane M., Tyrrell Kerin L., Warren Yumi A., Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile, 10.1016/j.anaerobe.2009.12.002
  55. Goldstein E. J. C., Citron D. M., Merriam C. V., Warren Y., Tyrrell K., Fernandez H. T., In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria, 10.1128/aac.47.6.1968-1971.2003
  56. Chilton C. H., Freeman J., Crowther G. S., Todhunter S. L., Wilcox M. H., Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model, 10.1093/jac/dks243
  57. Freeman J., Marquis M., Crowther G. S., Todhunter S. L., Fawley W. N., Chilton C. H., Moeck G., Lehoux D., Wilcox M. H., Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model, 10.1093/jac/dks309
  58. Chilton C. H., Freeman J., Baines S. D., Crowther G. S., Nicholson S., Wilcox M. H., Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery, 10.1093/jac/dkt160
  59. Arthur M, Depardieu F, Reynolds P, et al. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother. 1999;43(8):1875–80.
  60. Song Yang, Lunde Christopher S., Benton Bret M., Wilkinson Brian J., Studies on the Mechanism of Telavancin Decreased Susceptibility in a Laboratory-Derived Mutant, 10.1089/mdr.2012.0195
  61. Scherr Tyler D., Heim Cortney E., Morrison John M., Kielian Tammy, Hiding in Plain Sight: Interplay between Staphylococcal Biofilms and Host Immunity, 10.3389/fimmu.2014.00037
  62. Garzoni Christian, Kelley William L., Staphylococcus aureus: new evidence for intracellular persistence, 10.1016/j.tim.2008.11.005
  63. Belley A., Neesham-Grenon E., McKay G., Arhin F. F., Harris R., Beveridge T., Parr T. R., Moeck G., Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro, 10.1128/aac.00766-08
  64. Smith K., Gemmell C. G., Lang S., Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models, 10.1007/s10096-013-1883-z
  65. Gander Sarah, Kinnaird Andrew, Finch Roger, Telavancin: in vitro activity against staphylococci in a biofilm model, 10.1093/jac/dki198
  66. LaPlante K. L., Mermel L. A., In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains, 10.1128/aac.01642-08
  67. Chan C, Hardin TC, Smart JI. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections. Future Microbiol. 2015;1–14.
  68. Barcia-Macay M., Seral C., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages, 10.1128/aac.50.3.841-851.2006
  69. Seral C., Van Bambeke F., Tulkens P. M., Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular Staphylococcus aureus in Mouse J774 Macrophages, 10.1128/aac.47.7.2283-2292.2003
  70. Lemaire S., Kosowska-Shick K., Julian K., Tulkens P.M., Van Bambeke F., Appelbaum P.C., Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis, 10.1111/j.1469-0691.2008.02035.x
  71. Garcia L. G., Lemaire S., Kahl B. C., Becker K., Proctor R. A., Tulkens P. M., Van Bambeke F., Influence of the Protein Kinase C Activator Phorbol Myristate Acetate on the Intracellular Activity of Antibiotics against Hemin- and Menadione-Auxotrophic Small-Colony Variant Mutants of Staphylococcus aureus and Their Wild-Type Parental Strain in Human THP-1 Cells, 10.1128/aac.01031-12
  72. Garcia L. G., Lemaire S., Kahl B. C., Becker K., Proctor R. A., Denis O., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Activity of Antibiotics against Hemin- and Menadione-Dependent Small-Colony Variants of Staphylococcus aureus in Models of Extracellular (Broth) and Intracellular (THP-1 Monocytes) Infections, 10.1128/aac.00285-12
  73. Nguyen H. A., Denis O., Vergison A., Theunis A., Tulkens P. M., Struelens M. J., Van Bambeke F., Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains, 10.1128/aac.01145-08
  74. Nguyen H. A., Denis O., Vergison A., Tulkens P. M., Struelens M. J., Van Bambeke F., Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations, 10.1128/aac.01146-08
  75. Van Bambeke F., Carryn S., Seral C., Chanteux H., Tyteca D., Mingeot-Leclercq M.-P., Tulkens P. M., Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages, 10.1128/aac.48.8.2853-2860.2004
  76. Van Bambeke F., Saffran J., Mingeot-Leclercq M.-P., Tulkens P. M., Mixed-Lipid Storage Disorder Induced in Macrophages and Fibroblasts by Oritavancin (LY333328), a New Glycopeptide Antibiotic with Exceptional Cellular Accumulation, 10.1128/aac.49.5.1695-1700.2005
  77. Lemaire S., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Study of Macrophage Functions in Murine J774 Cells and Human Activated THP-1 Cells Exposed to Oritavancin, a Lipoglycopeptide with High Cellular Accumulation, 10.1128/aac.02475-13
  78. Baquir Beverlie, Lemaire Sandrine, Van Bambeke Françoise, Tulkens Paul M., Lin Lin, Spellberg Brad, Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin, 10.1093/cid/cir921
  79. Barcia-Macay M., Mouaden F., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts), 10.1093/jac/dkn120
  80. Arhin Francis F., McKay Geoffrey A., Beaulieu Sylvain, Sarmiento Ingrid, Parr Thomas R., Moeck Gregory, Time–kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes, 10.1016/j.ijantimicag.2009.08.012
  81. McKay G. A., Beaulieu S., Arhin F. F., Belley A., Sarmiento I., Parr T., Moeck G., Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium, 10.1093/jac/dkp126
  82. Vidaillac Céline, Parra-Ruiz Jorge, Rybak Michael Joseph, In vitro time–kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin, 10.1016/j.diagmicrobio.2011.09.002
  83. Coyle E. A., Rybak M. J., Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model, 10.1128/aac.45.3.706-709.2001
  84. Arhin Francis F., Sarmiento Ingrid, Parr Thomas R., Moeck Gregory, Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus, 10.1016/j.ijantimicag.2011.09.017
  85. Arhin Francis F., Sarmiento Ingrid, Moeck Gregory, Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA), 10.1016/j.ijantimicag.2012.12.004
  86. Lin Gengrong, Pankuch Glenn A., Appelbaum Peter C., Kosowska-Shick Klaudia, Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill, 10.1016/j.diagmicrobio.2012.04.003
  87. Leonard Steven N., Szeto Yong G., Zolotarev Maria, Grigoryan Ilona V., Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA), 10.1016/j.ijantimicag.2011.02.007
  88. Smith Jordan R., Barber Katie E., Hallesy Jessica, Raut Animesh, Rybak Michael J., Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models, 10.1128/aac.00773-15
  89. Goldstein B. P., Draghi D. C., Sheehan D. J., Hogan P., Sahm D. F., Bactericidal Activity and Resistance Development Profiling of Dalbavancin, 10.1128/aac.00620-06
  90. Baltch AL, Smith RP, Ritz WJ, et al. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1998;42(10):2564–8.
  91. Mercier RC, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother. 1997;41(6):1307–12.
  92. Zelenitsky SA, Booker B, Laing N, et al. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1999;43(3):592–7.
  93. Lin G., Pankuch G., Appelbaum P. C., Kosowska-Shick K., Antistaphylococcal Activity of Oritavancin and Its Synergistic Effect in Combination with Other Antimicrobial Agents, 10.1128/aac.02932-14
  94. Leonard S. N., Supple M. E., Gandhi R. G., Patel M. D., Comparative Activities of Telavancin Combined with Nafcillin, Imipenem, and Gentamicin against Staphylococcus aureus, 10.1128/aac.02127-12
  95. Lin G., Pankuch G. A., Ednie L. M., Appelbaum P. C., Antistaphylococcal Activities of Telavancin Tested Alone and in Combination by Time-Kill Assay, 10.1128/aac.01143-09
  96. JOHNSON D, FRITSCHE T, SADER H, JONES R, Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions, 10.1016/j.ijantimicag.2005.12.015
  97. Ambrose P. G., Drusano G. L., Craig W. A., In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans, 10.1093/cid/cis001
  98. Kaatz GW, Seo SM, Aeschlimann JR, et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42(4):981–3.
  99. Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 1999;43(1):115–20.
  100. Rupp M. E., Fey P. D., Longo G. M., Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model, 10.1093/jac/47.5.705
  101. Gerber J., Smirnov A., Wellmer A., Ragheb J., Prange J., Schutz E., Wettich K., Kalich S., Nau R., Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin, 10.1128/aac.45.7.2169-2172.2001
  102. Cabellos C., Fernandez A., Maiques J. M., Tubau F., Ardanuy C., Viladrich P. F., Linares J., Gudiol F., Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis, 10.1128/aac.47.6.1907-1911.2003
  103. Heine H. S., Bassett J., Miller L., Bassett A., Ivins B. E., Lehoux D., Arhin F. F., Parr T. R., Moeck G., Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax, 10.1128/aac.00360-08
  104. Hegde Sharath S, Janc James W, Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection, 10.1586/14787210.2014.979789
  105. Reyes N., Skinner R., Kaniga K., Krause K. M., Shelton J., Obedencio G. P., Gough A., Conner M., Hegde S. S., Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus, 10.1128/aac.49.10.4344-4346.2005
  106. Reyes N., Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus, 10.1093/jac/dkl222
  107. Xiong Y. Q., Hady W. A., Bayer A. S., Chen L., Kreiswirth B. N., Yang S.-J., Telavancin in Therapy of Experimental Aortic Valve Endocarditis in Rabbits Due to Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus, 10.1128/aac.00922-12
  108. Madrigal A. G., Basuino L., Chambers H. F., Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus, 10.1128/aac.49.8.3163-3165.2005
  109. Miro J. M., Garcia-de-la-Maria C., Armero Y., de-Lazzari E., Soy D., Moreno A., del Rio A., Almela M., Mestres C. A., Gatell J. M., Jimenez-de-Anta M.-T., Marco F., , Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus, 10.1128/aac.01266-06
  110. Crandon J. L., Kuti J. L., Nicolau D. P., Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model, 10.1128/aac.00062-10
  111. Stucki A., Gerber P., Acosta F., Cottagnoud M., Cottagnoud P., Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters, 10.1128/aac.50.2.770-773.2006
  112. Yin L.-Y., Calhoun J. H., Thomas T. S., Wirtz E. D., Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model, 10.1093/jac/dkn490
  113. Jabes D., Candiani G., Romano G., Brunati C., Riva S., Cavaleri M., Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model, 10.1128/aac.48.4.1118-1123.2004
  114. Andes D., Craig W. A., In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin, 10.1128/aac.01264-06
  115. Lefort A., Pavie J., Garry L., Chau F., Fantin B., Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin, 10.1128/aac.48.3.1061-1064.2004
  116. Baldoni Daniela, Furustrand Tafin Ulrika, Aeppli Sandrine, Angevaare Eline, Oliva Alessandra, Haschke Manuel, Zimmerli Werner, Trampuz Andrej, Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model, 10.1016/j.ijantimicag.2013.05.019
  117. Heine H. S., Purcell B. K., Bassett J., Miller L., Goldstein B. P., Activity of Dalbavancin against Bacillus anthracis In Vitro and in a Mouse Inhalation Anthrax Model, 10.1128/aac.00820-09
  118. Hegde S. S., Reyes N., Wiens T., Vanasse N., Skinner R., McCullough J., Kaniga K., Pace J., Thomas R., Shaw J.-P., Obedencio G., Judice J. K., Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria, 10.1128/aac.48.8.3043-3050.2004
  119. Boylan C. J., Campanale K., Iversen P. W., Phillips D. L., Zeckel M. L., Parr T. R., Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection, 10.1128/aac.47.5.1700-1706.2003
  120. Rubino C. M., Bhavnani S. M., Moeck G., Bellibas S. E., Ambrose P. G., Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials, 10.1128/aac.00176-15
  121. Belley A., Arhin F. F., Sarmiento I., Deng H., Rose W., Moeck G., Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection, 10.1128/aac.01428-12
  122. Lodise T. P., Butterfield J. M., Hegde S. S., Samara E., Barriere S. L., Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function, 10.1128/aac.00383-11
  123. Farkas A., Successful Target Attainment of Telavancin at Elevated MICs: Fact or Fiction?, 10.1128/aac.00609-12
  124. Dowell James A., Goldstein Beth P., Buckwalter Mary, Stogniew Martin, Damle Bharat, Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic, 10.1177/0091270008321273
  125. Dunne Michael W., Puttagunta Sailaja, Sprenger Craig R., Rubino Chris, Van Wart Scott, Baldassarre James, Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue, 10.1128/aac.04550-14
  126. Goldberg Michael R, Wong Shekman L, Shaw Jeng-Pyng, Kitt Michael M, Barriere Steven L, Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin, 10.1592/phco.30.1.35
  127. Bradley John S., Puttagunta Sailaja, Rubino Christopher M., Blumer Jeffrey L., Dunne Michael, Sullivan Janice E., Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of Age : , 10.1097/inf.0000000000000646
  128. The Medicines Company. Open-label, dose-finding, pharmacokinetics, safety and tolerability study of oritavancin in pediatric patients with suspected or confirmed bacterial infections [ identifier NCT02134301]. US National Institutes of Health, . Accessed 8 Nov 2015.
  129. Theravance Biopharma Antibiotics, Inc. An open-label study of the pharmacokinetics of a single dose of telavancin in pediatric subjects aged 1 to 17 years [ identifier NCT02013141]. US National Institutes of Health, . Accessed 8 Nov 2015.
  130. Mitra S, Saeed U, Havlichek DH, et al. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections. Infect Drug Resist. 2015;8:189–97.
  131. Barriere Steven L, ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections, 10.2217/fmb.10.138
  132. Barriere Steven L, The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia, 10.2217/fmb.14.4
  133. Ramdeen Sheena, Boucher Helen W, Dalbavancin for the treatment of acute bacterial skin and skin structure infections, 10.1517/14656566.2015.1075508
  134. Scott Lesley J., Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections, 10.1007/s40265-015-0430-x
  135. Pushkin Richard, Barriere Steven L., Wang Whedy, Corey G. Ralph, Stryjewski Martin E., Telavancin for Acute Bacterial Skin and Skin Structure Infections, aPost HocAnalysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance, 10.1128/aac.00471-15
  136. Seltzer E., Dorr M. B., Goldstein B. P., Perry M., Dowell J. A., Henkel T., , Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections, 10.1086/379015
  137. Stryjewski M. E., Chu V. H., O'Riordan W. D., Warren B. L., Dunbar L. M., Young D. M., Vallee M., Fowler V. G., Morganroth J., Barriere S. L., Kitt M. M., Corey G. R., , Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study, 10.1128/aac.50.3.862-867.2006
  138. Tice A., Oritavancin: A New Opportunity for Outpatient Therapy of Serious Infections, 10.1093/cid/cir1047
  139. Liapikou Adamantia, Torres Antoni, Emerging drugs on methicillin-resistantStaphylococcus aureus, 10.1517/14728214.2013.813480
  140. Rubinstein E., Lalani T., Corey G. R., Kanafani Z. A., Nannini E. C., Rocha M. G., Rahav G., Niederman M. S., Kollef M. H., Shorr A. F., Lee P. C., Lentnek A. L., Luna C. M., Fagon J.-Y., Torres A., Kitt M. M., Genter F. C., Barriere S. L., Friedland H. D., Stryjewski M. E., , Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens, 10.1093/cid/ciq031
  141. Lacy Melinda K., Stryjewski Martin E., Wang Whedy, Hardin Thomas C., Nogid Boris, Luke David R., Shorr Andrew F., Corey G. Ralph, Barriere Steven L., Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality, 10.1093/cid/civ536
  142. Corey G. R., Kollef M. H., Shorr A. F., Rubinstein E., Stryjewski M. E., Hopkins A., Barriere S. L., Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival, 10.1128/aac.02330-13
  143. Torres A., Rubinstein E., Corey G. R., Stryjewski M. E., Barriere S. L., Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure, 10.1093/jac/dkt490
  144. Bhavnani S. M., Passarell J. A., Owen J. S., Loutit J. S., Porter S. B., Ambrose P. G., Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia, 10.1128/aac.50.3.994-1000.2006
  145. Stryjewski Martin E, Lentnek Arnold, O’Riordan William, Pullman John, Tambyah Paul Anantharajah, Miró Jose M, Fowler Jr Vance G, Barriere Steven L, Kitt Michael M, Corey G Ralph, A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study, 10.1186/1471-2334-14-289
  146. Corey G. R., Rubinstein E., Stryjewski M. E., Bassetti M., Barriere S. L., Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus, 10.1093/cid/ciu971
  147. Joson J., Grover C., Downer C., Pujar T., Heidari A., Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure, 10.1093/jac/dkr234
  148. Marcos L. A., Camins B. C., Successful Treatment of Vancomycin-Intermediate Staphylococcus aureus Pacemaker Lead Infective Endocarditis with Telavancin, 10.1128/aac.00857-10
  149. Kaushal R., Hassoun A., Successful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancin, 10.1093/jac/dks165
  150. Twilla J. D., Gelfand M. S., Cleveland K. O., Usery J. B., Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis, 10.1093/jac/dkr329
  151. Brinkman Mary Beth, Fan Kaili, Shiveley Renee L, Van Anglen Lucinda J, Successful Treatment of Polymicrobial Calcaneal Osteomyelitis with Telavancin, Rifampin, and Meropenem, 10.1345/aph.1q331
  152. Raad I., Darouiche R., Vazquez J., Lentnek A., Hachem R., Hanna H., Goldstein B., Henkel T., Seltzer E., Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens, 10.1086/427283
  153. Cho JC, Estrada SJ, Beltran AJ, et al. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther. 2015. doi: 10.1111/jcpt.12306 .
  154. Barriere Steven, Genter Fredric, Spencer Elizabeth, Kitt Michael, Hoelscher David, Morganroth Joel, Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy Subjects, 10.1177/0091270004266620
  155. Dunne Michael W., Zhou Meijian, Darpo Borje, A thorough QT study with dalbavancin: A novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections, 10.1016/j.ijantimicag.2014.12.021
  156. Stryjewski Martin E., Graham Donald R., Wilson Samuel E., O’Riordan William, Young David, Lentnek Arnold, Ross Douglas P., Fowler Vance G., Hopkins Alan, Friedland H. David, Barriere Steven L., Kitt Michael M., Corey G. Ralph, , Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms, 10.1086/587896
  157. Saravolatz Louis D., Stein Gary E., Oritavancin: A Long-Half-Life Lipoglycopeptide, 10.1093/cid/civ311
  158. Corey G. Ralph, Good Samantha, Jiang Hai, Moeck Greg, Wikler Matthew, Green Sinikka, Manos Paul, Keech Richard, Singh Rajesh, Heller Barry, Bubnova Natalia, O'Riordan William, Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study, 10.1093/cid/ciu778
  159. Corey G. Ralph, Kabler Heidi, Mehra Purvi, Gupta Sandeep, Overcash J. Scott, Porwal Ashwin, Giordano Philip, Lucasti Christopher, Perez Antonio, Good Samantha, Jiang Hai, Moeck Greg, O'Riordan William, Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections, 10.1056/nejmoa1310422
  160. Ullman Mary A., Rotschafer John C., Glycopeptides, Lipopeptides, and Lipoglycopeptides, Drug Interactions in Infectious Diseases (2011) ISBN:9781617792120 p.333-353, 10.1007/978-1-61779-213-7_10
  161. Tam Vincent H., Ledesma Kimberly R., Bowers Dana R., Zhou Jian, Truong Luan D., Kidney Injury Associated with Telavancin Dosing Regimen in an Animal Model, 10.1128/aac.05002-14
  162. Barriere S. L., Goldberg M. R., Janc J. W., Higgins D. L., Macy P. A., Adcock D. M., Effects of telavancin on coagulation test results : Telavancin and coagulation tests, 10.1111/j.1742-1241.2011.02668.x
  163. Wong Shekman L, Goldberg Michael R, Ballow Charles H, Kitt Michael M, Barriere Steven L, Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double-Blind, Crossover Study in Healthy Subjects, 10.1592/phco.30.2.136
  164. Wong Shekman L., Sörgel Fritz, Kinzig Martina, Goldberg Michael R., Kitt Michael M., Barriere Steven L., Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy Participants, 10.1177/0091270009337133
  165. Antonanzas Fernando, Lozano Carmen, Torres Carmen, Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus, 10.1007/s40273-014-0242-y
  166. Laohavaleeson Somvadee, Barriere Steven L, Nicolau David P, Kuti Joseph L, Cost-Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections, 10.1592/phco.28.12.1471
  167. Li Yunfei, He Yingchun, Sheng Yucheng, Wang Kun, Wang Jingjing, Huang Jihan, Yang Juan, Zheng Qingshan, Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs, 10.1586/14787210.2013.851600
  168. Henson Karl Evans R, Levine Miriam T, Wong Eunice Ann H, Levine Donald P, Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile, 10.1586/14787210.2015.1068118
  169. , White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens, 10.1093/cid/cis688
  170. Committee for Human Medicinal Products, EMA. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. . Accessed 6 Sep 2015.
  171. Kumar Atul, Mann Henry J., Keshtgarpour Mani, Flynn Michael A., Deng Hong, Far Adel Rafai, Parr Thomas R., Moriarty Susan R., In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers, 10.5301/ijao.5000008
  172. Vilay A. Mary, Shah Krishna H., Churchwell Mariann D., Patel Jignesh H., DePestel Daryl D., Mueller Bruce A., Modeled Dalbavancin Transmembrane Clearance during Intermittent and Continuous Renal Replacement Therapies, 10.1159/000316685
  173. Mendes Rodrigo E., Farrell David J., Sader Helio S., Jones Ronald N., Oritavancin Microbiologic Features and Activity Results From the Surveillance Program in the United States, 10.1093/cid/cir923
  174. Jones Ronald N., Sader Helio S., Flamm Robert K., Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011), 10.1016/j.diagmicrobio.2012.11.024
  175. McCurdy Sandra P., Jones Ronald N., Mendes Rodrigo E., Puttagunta Sailaja, Dunne Michael W., In VitroActivity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program: TABLE 1, 10.1128/aac.00274-15
  176. Leighton A., Gottlieb A. B., Dorr M. B., Jabes D., Mosconi G., VanSaders C., Mroszczak E. J., Campbell K. C. M., Kelly E., Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers, 10.1128/aac.48.3.940-945.2004
  177. Kiem Sungmin, Schentag Jerome J, Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin ResistantStaphylococcus aureus, 10.3947/ic.2014.46.4.219
  178. Gotfried M. H., Shaw J.-P., Benton B. M., Krause K. M., Goldberg M. R., Kitt M. M., Barriere S. L., Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics, 10.1128/aac.00875-07
  179. Lodise T. P., Gotfried M., Barriere S., Drusano G. L., Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation, 10.1128/aac.01110-07
  180. Stryjewski M. E., O'Riordan W. D., Lau W. K., Pien F. D., Dunbar L. M., Vallee M., Fowler V. G., Chu V. H., Spencer E., Barriere S. L., Kitt M. M., Cabell C. H., Corey G. R., , Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria, 10.1086/429914
  181. Jauregui L. E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., Krause D., Satilovs I., Endzinas Z., Breaux J., O'Riordan W., Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections, 10.1086/497271
  182. Boucher HW, Talbot GH, Dunne MW. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014;371(12):1161–2.
  183. Drugs for MRSA Skin and Soft-Tissue Infections, 10.1001/jama.2014.13385